Sildenafil Treatment of Women With Antidepressant-Associated Sexual Dysfunction: A Randomized Controlled Trial | Depressive Disorders | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
 Trends in antidepressant use. AHRQ News and Numbers. Rockville, MD: Agency for Healthcare Research and Quality; May 16, 2005.
Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction.  J Clin Psychiatry. 2001;62:(Suppl 3)  10-2111229449PubMedGoogle Scholar
Lin EHB, Von Korff M, Katon W,  et al.  The role of the primary care physician inpatients' adherence to antidepressant therapy.  Med Care. 1995;33(1):67-747823648PubMedGoogle ScholarCrossref
Rudkin L, Taylor MJ, Hawton K. Strategies for managing sexual dysfunction induced by antidepressant medication.  Cochrane Database Syst Rev. 2004;(4):CD00338215495050PubMedGoogle Scholar
Kessler RC, Berglund P, Demler O,  et al.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).  JAMA. 2003;289(23):3095-310512813115PubMedGoogle ScholarCrossref
Zimmerman M, Posternak M, Friedman M,  et al.  Which factors influence psychiatrists' selection of antidepressants?  Am J Psychiatry. 2004;161(7):1285-128915229063PubMedGoogle ScholarCrossref
Alex J, Mitchell AJ, Selmes T. Why don't patients take their medicine? reasons and solutions in psychiatry.  Adv Psychiatr Treat. 2007;13(5):336-346Google ScholarCrossref
Ekselius L, von Knorring L. Effect on sexual function of long-term treatment with selective serotonin reuptake inhibitors in depressed patients treated in primary care.  J Clin Psychopharmacol. 2001;21(2):154-16011270911PubMedGoogle ScholarCrossref
Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA.Sildenafil Study Group.  Oral sildenafil in the treatment of erectile dysfunction.  N Engl J Med. 1998;338(20):1397-14049580646PubMedGoogle ScholarCrossref
Rosen R, Shabsigh R, Berber M,  et al.  Efficacy and tolerability of vardenafil in men with mild major depressive disorder and erectile dysfunction: the depression related improvement with vardenafil for erectile response (DRIVER) study.  Am J Psychiatry. 2006;163(1):79-8716390893PubMedGoogle ScholarCrossref
Nurnberg HG, Hensley PL, Gelenberg AJ, Fava M, Lauriello J, Paine S. Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial.  JAMA. 2003;289(1):56-6412503977PubMedGoogle ScholarCrossref
Park K, Moreland RB, Goldstein I, Atala A, Traish A. Sildenafil inhibits phosphodiesterase type 5 in human clitoral corpus cavernosum smooth muscle.  Biochem Biophys Res Commun. 1998;249(3):612-6179731184PubMedGoogle ScholarCrossref
Basson R, McInnes R, Smith MD, Hodgson G, Koppiker N. Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder.  J Womens Health Gend Based Med. 2002;11(4):367-37712150499PubMedGoogle ScholarCrossref
Caruso S, Intelisano G, Lupo L, Agnello C. Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double-blind, cross-over, placebo-controlled study.  BJOG. 2001;108(6):623-62811426898PubMedGoogle Scholar
Berman JR, Berman LA, Toler SM, Gill J, Haughie S.Sildenafil Study Group.  Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder: a double-blind, placebo controlled study.  J Urol. 2003;170(6 Pt 1):2333-233814634409PubMedGoogle ScholarCrossref
Basson R, Brotto LA. Sexual psychophysiology and effects of sildenafil citrate in oestrogenised women with acquired genital arousal disorder and impaired orgasm: a randomised controlled trial.  BJOG. 2003;110(11):1014-102414592587PubMedGoogle ScholarCrossref
Caruso S, Intelisano G, Farina M, Di Mari L, Agnello C. The function of sildenafil on female sexual pathways: a double-blind, cross-over, placebo-controlled study.  Eur J Obstet Gynecol Reprod Biol. 2003;110(2):201-20612969584PubMedGoogle ScholarCrossref
Nurnberg HG, Hensley P, Lauriello J, Parker L, Keith SJ. Sildenafil for women patients with antidepressant-induced sexual dysfunction.  Psychiatr Serv. 1999;50(8):1076-107810445658PubMedGoogle Scholar
Fava M, Rankin MA, Alpert JE, Nierenberg AA, Worthington JJ. An open trial of oral sildenafil in antidepressant-induced sexual dysfunction.  Psychother Psychosom. 1998;67(6):328-3319817955PubMedGoogle ScholarCrossref
Min K, Munarriz R, Kim NN, Goldstein I, Traish A. Effects of ovariectomy and estrogen and androgen treatment on sildenafil-mediated changes in female genital blood flow and vaginal lubrication in the animal model.  Am J Obstet Gynecol. 2002;187(5):1370-137612439533PubMedGoogle ScholarCrossref
Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment.  Arch Gen Psychiatry. 1998;55(7):580-5929672048PubMedGoogle ScholarCrossref
American Psychiatric Association.  Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994
Hamilton M. A rating scale for depression.  J Neurol Neurosurg Psychiatry. 1960;23:56-6214399272PubMedGoogle ScholarCrossref
Frank E, Prien RF, Jarrett RB,  et al.  Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence.  Arch Gen Psychiatry. 1991;48(9):851-8551929776PubMedGoogle ScholarCrossref
Hamilton M. The assessment of anxiety states by rating.  Br J Med Psychol. 1959;32(1):50-5513638508PubMedGoogle ScholarCrossref
Guy W. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: National Institute of Mental Health; 1976
Quirk FH, Heiman JR, Rosen RC, Laan E, Smith MD, Boolell M. Development of a sexual function questionnaire for clinical trials of female sexual dysfunction.  J Womens Health Gend Based Med. 2002;11(3):277-28911988137PubMedGoogle ScholarCrossref
McGahuey CA, Gelenberg AJ, Laukes CA,  et al.  The Arizona Sexual Experience Scale (ASEX): reliability and validity.  J Sex Marital Ther. 2000;26(1):25-4010693114PubMedGoogle ScholarCrossref
Nurnberg HG, Gelenberg A, Fava M, Hensley PL, Lauriello J, Paine S. The Sexual Function Inventory: A Screening Instrument for Antidepressant-Associated Sexual Dysfunction. New Orleans, LA: American Psychiatric Association; 2001
Labbate LA, Lare SB. Sexual dysfunction in male psychiatric outpatients: validity of the Massachusetts General Hospital Sexual Functioning Questionnaire.  Psychother Psychosom. 2001;70(4):221-22511408842PubMedGoogle ScholarCrossref
Piazza LA, Markowitz JC, Kocsis JH,  et al.  Sexual functioning in chronically depressed patients treated with SSRI antidepressants: a pilot study.  Am J Psychiatry. 1997;154(12):1757-17599396959PubMedGoogle Scholar
Davis SR, Davison SL, Donath S, Bell RJ. Circulating androgen levels and self-reported sexual function in women.  JAMA. 2005;294(1):91-9615998895PubMedGoogle ScholarCrossref
Laan E, van Lunsen RH, Everaerd W, Riley A, Scott E, Boolell M. The enhancement of vaginal vasocongestion by sildenafil in healthy premenopausal women.  J Womens Health Gend Based Med. 2002;11(4):357-36512150498PubMedGoogle ScholarCrossref
Kilicarslan H, Bagcivan I, Yildirim MK, Sarac B, Kaya T. Effect of hypothyroidism on the NO/cGMP pathway of corpus cavernosum in rabbits.  J Sex Med. 2006;3(5):830-83716942528PubMedGoogle ScholarCrossref
Berman JR, Berman LA, Lin H,  et al.  Effect of sildenafil on subjective and physiological parameters of the female sexual response in women with sexual arousal disorder.  J Sex Marital Ther. 2001;27(5):411-42011554201PubMedGoogle ScholarCrossref
Angulo J, Cuevas P, Cuevas B, Bischoff E, Sáenz de Tejada I. Vardenafil enhances clitoral and vaginal blood flow responses to pelvic nerve stimulation in female dogs.  Int J Impot Res. 2003;15(2):137-14112789394PubMedGoogle ScholarCrossref
Seidman SN, Pesce V, Roose SP. High dose sildenafil citrate for selective serotonin reuptake inhibitor-associated ejaculatory delay: open clinical trial.  J Clin Psychiatry. 2003;64(6):721-72512823089PubMedGoogle ScholarCrossref
Nurnberg HG, Siegel R. Effects of sildenafil citrate treatment on ejaculatory/orgasm delay and erectile dysfunction in serotonergic antidepressant-associated sexual dysfunction [abstract].  J Urol. 2006;175(4):300Google Scholar
Nurnberg HG, Seidman SN, Gelenberg AJ, Fava M, Rosen R, Shabsigh R. Depression, antidepressant therapies, and erectile dysfunction: clinical trials of sildenafil citrate (Viagra) in treated and untreated patients with depression.  Urology. 2002;60(2):(suppl 2)  58-6612414334PubMedGoogle ScholarCrossref
Snedecor GW, Cochran WG. Statistical Methods. 7th ed. Ames: Iowa State University Press; 1980
Original Contribution
July 23 2008

Sildenafil Treatment of Women With Antidepressant-Associated Sexual Dysfunction: A Randomized Controlled Trial

Author Affiliations

Author Affiliations: Department of Psychiatry, Health Sciences Center, University of New Mexico School of Medicine, Albuquerque (Drs Nurnberg and Hensley, and Ms Paine); The Croft Group, San Antonio, Texas (Dr Croft); the Kinsey Institute for Research in Sex, Gender, and Reproduction, Indiana University, Bloomington (Dr Heiman); and Stanford University School of Medicine, Palo Alto, California (Dr Debattista).

JAMA. 2008;300(4):395-404. doi:10.1001/jama.300.4.395

Context Antidepressant-associated sexual dysfunction is a common adverse effect that frequently results in premature medication treatment discontinuation and for which no treatment has demonstrated efficacy in women.

Objective To evaluate the efficacy of sildenafil for sexual dysfunction associated with selective and nonselective serotonin reuptake inhibitors (SRIs) in women.

Design, Setting, and Participants An 8-week prospective, parallel-group, randomized, double-blind, placebo-controlled clinical trial conducted between September 1, 2003, and January 1, 2007, at 7 US research centers that included 98 previously sexually functioning, premenopausal women (mean [SD] age 37.1 [6] years) whose major depression was remitted by SRIs but who were also experiencing sexual dysfunction.

Intervention Forty-nine patients were randomly assigned to take sildenafil or placebo at a flexible dose starting at 50 mg adjustable to 100 mg before sexual activity.

Main Outcome Measures The primary outcome measure was the mean difference in change from baseline to study end (ie, lower ordinal score) on the Clinical Global Impression sexual function scale. Secondary measures included the Female Sexual Function Questionnaire, the Arizona Sexual Experience scale-female version, the University of New Mexico Sexual Function Inventory-female version, a sexual activity event log, and the Hamilton Depression Rating scale. Hormone levels were also assessed.

Results In an intention-to-treat analysis, women treated with sildenafil had a mean Clinical Global Impression–sexual function score of 1.9 (95% confidence interval [CI], 1.6-2.3) compared with those taking placebo (1.1; 95% CI, 0.8-1.5), with a mean end point difference of 0.8 (95% CI, 0.6-1.0; P = .001). Assigning baseline values carried forward to the 22% of patients who prematurely discontinued resulted in a mean end point in the sexual function score of 1.5 (95% CI, 1.1-1.9) among women taking sildenafil compared with 0.9 (95% CI, 0.6-1.3) among women taking placebo with a mean end point difference of 0.6 (95% CI, 0.3-0.8; P = .03). Baseline endocrine levels were within normal limits and did not differ between groups. The mean (SD) Hamilton scores for depression remained consistent with remission in both groups (4.0 [3.6]; P = .90). Headache, flushing, and dyspepsia were reported frequently during treatment, but no patients withdrew because of serious adverse effects.

Conclusion In this study population, sildenafil treatment of sexual dysfunction in women taking SRIs was associated with a reduction in adverse sexual effects.

Trial Registration Identifier: NCT00375297